Ace the Case: A 71-Year-Old Woman With Multiple Myeloma Progressing Following Three Lines of Therapy
Support for this activity has been provided through educational grants from Adaptive Biotechnologies; Amgen; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; Oncopeptides; and Sanofi Genzyme.
Click Here to Manage Email Alerts
This continuing medical education activity is jointly provided by
This educational activity utilizes a case study to discuss the treatment options that are available for multiple myeloma (MM) patients who relapse several times and have been on multidrug combinations.
This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with multiple myeloma.
Upon successful completion of this educational activity, participants should be better able to incorporate the use of novel agent/monoclonal antibody–based regimens for newly diagnosed or relapsed/refractory MM patients based on currently available evidence
Online interactive case-based activity
Nina Shah, MD
Associate Professor of Medicine
University of California San Francisco
San Francisco, California
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity enables the participant to earn 0.25 Maintenance of Certification (MOC) points in the American Board of Internal Medicine’s (ABIM) MOC program. Participants who opt in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to the ACCME for the purpose of granting ABIM MOC points.
This enduring material is approved for 1 year from the date of original release, December 9, 2020 to December 9, 2021.
How to Participate in This Activity and Obtain CME Credit
To participate in this CME activity, you must read the learning objective, review the case, and complete the CME posttest and evaluation. Upon receipt of the completed materials, Penn State College of Medicine will issue an AMA PRA Category 1 Credit™ certificate.
For questions regarding CME credit, please contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference course # G6643-21-T.
In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.
Nina Shah, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Amgen, Bristol Myers Squibb, CareDx, Genentech, GlaxoSmithKline, Indapta Therapeutics, Karyopharm Therapeutics, Nektar Therapeutics, Oncopeptides, Precision BioSciences, Sanofi, Seattle Genomics, Surface Oncology
Research Grant: Bluebird Bio, Celgene/Bristol Myers Squibb, Janssen, Sutro Biopharma, TeneoBio
Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Multiple Myeloma Research Foundation
Mary DeRome, Director of Medical Communications and Education, has disclosed no relevant financial relationships.
Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Kristen Petro Slade, Director of Operations, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.
Karen Tenaglia, Project Manager, has disclosed no relevant financial relationships.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine; RedMedEd; the Multiple Myeloma Research Foundation; Adaptive Biotechnologies; Amgen; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; Oncopeptides; and Sanofi Genzyme do not recommend the use of any agent outside the labeled indications.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Penn State College of Medicine; RedMedEd; the Multiple Myeloma Research Foundation; Adaptive Biotechnologies; Amgen; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; Oncopeptides; or Sanofi Genzyme. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
CME credit for this activity is provided by Penn State College of Medicine. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to Penn State College of Medicine so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. Penn State College of Medicine or RedMedEd may use the information you provide on this site to contact you about your CME credit or other relevant educational activities. For more information, contact ContinuingEd@hmc.psu.edu or firstname.lastname@example.org.
© 2020. This CME-certified program is held as copyrighted by Penn State College of Medicine, MMRF, and RedMedEd. Through this notice, Penn State College of Medicine, MMRF, and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.